Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: 16 week results of a phase 3 randomised, double-blind, placebo-controlled trial in patients with prior inadequate response or intolerance to 1 or 2 tumour necrosis factor inhibitors
SWISS MEDICAL WEEKLY（2019）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined